A detailed history of Janney Montgomery Scott LLC transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 140,911 shares of INMB stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,911
Previous 163,559 13.85%
Holding current value
$1.24 Million
Previous $1.84 Million 10.1%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$10.53 - $14.01 $238,483 - $317,298
-22,648 Reduced 13.85%
140,911 $1.66 Million
Q4 2023

Feb 07, 2024

SELL
$6.6 - $11.52 $615,964 - $1.08 Million
-93,328 Reduced 36.33%
163,559 $1.84 Million
Q3 2023

Nov 08, 2023

BUY
$6.61 - $10.9 $214,706 - $354,053
32,482 Added 14.47%
256,887 $1.74 Million
Q2 2023

Jul 26, 2023

SELL
$6.5 - $10.09 $97,779 - $151,783
-15,043 Reduced 6.28%
224,405 $2.04 Million
Q1 2023

Apr 28, 2023

BUY
$6.01 - $10.18 $89,362 - $151,366
14,869 Added 6.62%
239,448 $1.55 Million
Q4 2022

Feb 01, 2023

BUY
$6.31 - $7.96 $183,576 - $231,580
29,093 Added 14.88%
224,579 $1.42 Million
Q3 2022

Oct 25, 2022

SELL
$6.91 - $10.44 $109,399 - $165,286
-15,832 Reduced 7.49%
195,486 $1.21 Million
Q2 2022

Aug 03, 2022

SELL
$5.48 - $8.97 $270,668 - $443,046
-49,392 Reduced 18.95%
211,318 $1.73 Million
Q1 2022

May 04, 2022

BUY
$6.42 - $11.39 $942,430 - $1.67 Million
146,796 Added 128.87%
260,710 $2.2 Million
Q4 2021

Jan 27, 2022

BUY
$9.97 - $20.38 $145,472 - $297,364
14,591 Added 14.69%
113,914 $1.16 Million
Q3 2021

Oct 29, 2021

BUY
$14.13 - $27.85 $593,219 - $1.17 Million
41,983 Added 73.22%
99,323 $1.93 Million
Q2 2021

Jul 26, 2021

BUY
$9.29 - $19.33 $532,688 - $1.11 Million
57,340 New
57,340 $1.01 Million

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $158M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.